Mediar Therapeutics has dosed the first subject in the Phase II WISPer trial of its investigational therapy, MTX-463, for IPF ...

Mediar Therapeutics, Inc., a clinical-stage biotechnology company advancing first-in-class therapies designed to halt fibrosis, today announced the first patient has been dosed in its Phase 2 WISPer ...

MTX-463 is a first-in-class human IgG1 antibody designed to neutralize WISP1-mediated fibrotic signaling in several debilitating diseases. The Phase 1 study was recently completed in healthy ...

MTX-463 is a first-in-class human IgG1 antibody designed to neutralize WISP1-mediated fibrotic signaling in several debilitating diseases. The Phase 1 study was recently completed in healthy ...

The deal, which includes up to $687 million in milestones, gives Lilly global rights to the anti-WISP1 antibody MTX-463. Researchers have linked WISP1 to fibrosis progression, leading Mediar to ...

"This collaboration supports our unique myofibroblast-directed approach to treating fibrotic diseases and our mission to bring first-in-class therapies to patients with high unmet medical need ...